Latest Regulatory News

Neurizon Therapeutics faces a delay in FDA review for its lead ALS therapy NUZ-001, with a new decision expected by early October amid agency-wide staffing challenges.

Magnetite Mines Limited has announced a pro rata renounceable rights issue to raise up to $2.65 million, aiming to advance its flagship Razorback iron ore project in South Australia. The offer includes free attaching options and is partially underwritten, reflecting the company’s strategic push towards securing funding and completing key project milestones.

EPX Limited has raised $2 million through a discounted share placement to existing institutional investors, aiming to fuel sales expansion, explore M&A opportunities, and enhance its technology platform.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Alice Queen Limited has formally lodged a 15-year mining lease application for its Horn Island Gold Project, marking a significant step forward in its decade-long exploration journey and attracting strong partnership interest.

Venus Metals Corporation has updated its Mineral Resource Estimate for the Bellchambers Gold Deposit and Rangeview Prospect near Sandstone, revealing a notable increase in measured resources and securing a mining lease that advances the project towards development.

Sarama Resources Ltd reported a $1.22 million net loss for the first half of 2025, while completing a $2.7 million equity placement and acquiring a majority stake in the Mt Venn Gold Project in Western Australia.

Adriatic Metals shareholders have overwhelmingly approved Dundee Precious Metals’ recommended acquisition scheme, clearing a major hurdle toward completion. Key regulatory approvals are in place, with the final court sanction hearing scheduled for late August.

Laramide Resources has made significant progress in advancing its uranium projects across the US, Australia, and Kazakhstan, highlighted by key permitting milestones under the US FAST-41 framework and a successful $12 million private placement to fund development.

Laramide Resources Ltd. reported a reduced net loss of CAD 1.05 million for H1 2025, converting USD 3.5 million of debt into equity and securing a $12 million private placement to bolster its uranium exploration projects.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

HealthCo Healthcare and Wellness REIT reported a substantial $89.3 million loss for FY25, driven by tenant payment issues and portfolio downsizing, leading to suspended distributions and a debt facility extension.